科学研究 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure
Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis
Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?
Active SB-P Versus Conventional Approach to the Protection of High-Risk Side Branches: The CIT-RESOLVE Trial
Positive remodeling at 3 year follow up is associated with plaque-free coronary wall segment at baseline: a serial IVUS study
Successful bailout stenting strategy against lethal coronary dissection involving left main bifurcation
Management of left main disease: an update
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance

|<<... 108 109 110 111 112 113 114 ...>>|

Review Article

2020 May 28.

JOURNAL：Heart Fail Rev.

Article Link

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

D Farmakis, C Chrysohoou, G Giamouzis et al.

11805

Keywords: AF; direct oral anticoagulants; HF; non-vitamin k antagonist oral anticoagulants; rate control; rhythm control

ABSTRACT

Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.